News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week In Review: BGI Plans $250 Million Shenzhen IPO



3/20/2017 9:20:05 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
BGI Genomics, the contract sequencing and diagnostics divisions of the giant China genomics sequencing company BGI, filed for a $250 million IPO on the Shenzhen Chi-Next exchange; Shandong Luoxin Pharma of Shanghai received a $301 million privatization offer from management and Ally Bridge Group; Fosun Pharma completed a $90 million acquisition of Breas Medical, a Swedish device company; Suzhou Ribo, a siRNA pharma, raised $39 million in a B round led by SDIC; vaccine maker Shenzhen Kangtai's stock price has risen 12-fold over six weeks following its modest $20 million Shenzhen IPO; Shanghai Newsummit in-licensed rights to a novel antibody targeting Hepatitis C virus from the UK's MRC Technology; Jiangsu Nhwa Pharma acquired China rights to an extended-release form anti-psychotic drug from Zysis of the UK; and Pfizer was CFDA approved to market a novel oral treatment for rheumatoid arthritis in China.

Read at BioSpace.com


comments powered by Disqus
BGI
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES